The Innovative Medicines Initiative (IMI) is a unique public/private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA) aimed at accelerating the discovery and development of new and better medicines by addressing bottlenecks in the R&D process. IMI brings together interested EFPIA members with the most relevant EU based biotechnology companies, universities, hospitals, patient organizations, and regulators in strategic and focused consortia. Each consortium has the task of conducting collaborative research in a selected area and disseminating their results and know-how.